Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03677141
Title A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche

diffuse large B-cell lymphoma

non-Hodgkin lymphoma



Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Cyclophosphamide + Doxorubicin + Mosunetuzumab + Polatuzumab vedotin-piiq + Prednisone

Cyclophosphamide + Doxorubicin + Mosunetuzumab + Prednisone + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | AUT

No variant requirements are available.